Pathios Therapeutics
Oxford
About Pathios Therapeutics
Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer. Pathios Therapeutics concentrates on the development of small molecule inhibitors targeting the pH-sensing G protein-coupled receptor GPR65. These inhibitors aim to counteract the immunosuppressive polarization of immune cells, such as tumor-associated macrophages, mediated by GPR65. This polarization is stimulated by the acidic tumor microenvironment commonly found in various cancers.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $38.9M
- Funding stage: Early Stage Venture
- Last round: Series B (Apr 2024)
- Website: pathiostherapeutics.com
- Phone: +44 1865 292 039
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/pathios-therapeutics-82344 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.